Enzo Biochem Inc. (ENZ)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: SERVICES-MEDICAL LABORATORIES

60 EXECUTIVE BLVD FARMINGDALE, NY 11735

Enzo Biochem is a life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics, and a provider of test services, including esoteric tests, to the medical community. Co. has three segments: Enzo Clinical Labs, which provides routine and esoteric clinical laboratory tests or procedures used in general patient care; Enzo Life Sciences, which manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers; and Enzo Therapeutics, which is a biopharmaceutical venture that focuses in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Data as of 2020-08-09
Market Cap121.164 Million Shares Outstanding47.891 Million Avg 30-day Volume1.525 Million
P/E Ratio Dividend Yield EPS-0.65
Price/Sales2.145 Price cash flow ratio10.7 Price free cash flow ratio-9.4
Book Value1.3 Price to Tangible Book2.23 Alpha-0.01
Short Interest Ratio1.52 % Short Interest to Float5.2 R-squared0.216582
BETA1.80376 52-week High/Low4.85 / 1.56 Stddev0.162983
View SEC Filings from ENZ instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 77 21 (1.38%)
Aggregate 13F shares on 03/31/2020: 28.835 Million 21.504 Million
Aggregate 13F shares on 12/31/2019: 32.21 Million 24.384 Million
Percent change: -10.48% -11.81%
Funds creating new positions: 8 2
Funds Adding to an existing position: 22 5
Funds closing out their position: 11 7
Funds reducing their position: 27 10
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENZ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENZ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LAZAR MELVIN F

  • Director
225,000 2020-05-13 0

PERLYSKY DOV

  • Director
0 2020-04-23 1

BLANK FABIAN

  • Director
0 2020-04-23 2

FISCHER REBECCA J.

  • Director
0 2020-04-23 2

CLEMENS PETER J IV

  • Director
0 2020-04-23 4

RABBANI ELAZAR CHIEF EXECUTIVE OFFICER

  • Officer
0 2020-02-24 2

WEINER BARRY W PRESIDENT AND TREASURER

  • Officer
  • Director
0 2020-02-24 2

BENCH DAVID CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-24 3

HARBERT MANAGEMENT CORP

HARBERT DISCOVERY FUND, LP

HARBERT DISCOVERY FUND GP, LLC

HARBERT DISCOVERY CO-INVESTMENT FUND I, LP

HARBERT DISCOVERY CO-INVESTMENT FUND I GP, LLC

HARBERT FUND ADVISORS, INC.

BRYANT JOHN F.

LUCAS KENAN

HARBERT RAYMOND J

  • 10% Owner
5,620,681 2019-08-16 1

BORTZ GREGORY M.

  • Director
93,699 2019-01-14 0

O'BRIEN JAMES MICHAEL EVP OF FINANCE

  • Officer
0 2019-01-03 0

HANNA BRUCE A.

  • Director
0 2019-01-03 0

GOLDBERG DAVID C CHIEF OPERATING OFFICER

  • Officer
34,051 2017-11-17 0

KRENITSKY KEVIN PRESIDENT

  • Officer
0 2016-06-13 0

KASTEN BERNARD L

  • Director
0 2016-01-06 0

DELUCCA JOHN

  • Director
32,343 2015-03-04 0

BASS HERBERT B VP OF FINANCE

  • Officer
0 2014-01-17 0

CRESCENZO ANDREW R. SENIOR VP OF FINANCE

  • Officer
0 2014-01-17 0

WHITELEY ANDREW P COO, ENZO LIFE SCIENCES, INC.

  • Officer
0 2014-01-17 0

KENT STEPHEN B H

  • Director
0 2012-01-26 0

BALEZENTIS CARL W PRES., ENZO LIFE SCIENCES

  • Officer
25,950 2010-12-15 0

GERSON IRWIN

  • Director
0 2010-03-04 0

RABBANI SHAHRAM K TREASURER, SECRETARY

  • Officer
  • Director
1,539,392 2009-07-01 0

FISCHETTE CHRISTINE PRES., ENZO THERAPEUTICS, INC.

  • Officer
11,500 2009-01-22 0

SIAS JOHN B

  • Director
173,087 2008-09-26 0

KELKER NORMAN E SENIOR VICE PRESIDENT

  • Officer
110,855 2008-09-23 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments